ӳ��ý

Cancer Program

Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records.

Zheng C, Khan A, Ritter D, et al. Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records. Cell reports. Medicine. 2025;6(9):102359. doi:10.1016/j.xcrm.2025.102359

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Siegel F, Siegel S, Kotýnková K, et al. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery. 2025. doi:10.1158/2159-8290.CD-25-0605

Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs.

Sadagopan A, Carson M, Zamurs EJ, et al. Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs. Nature chemical biology. 2025. doi:10.1038/s41589-025-02051-7

Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma.

Yang J, Wang C, Fu D, et al. Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma. Nature communications. 2025;16(1):8151. doi:10.1038/s41467-025-62878-5

CRISPR-based therapeutic genome editing for inherited blood disorders.

Levesque S, Bauer DE. CRISPR-based therapeutic genome editing for inherited blood disorders. Nature reviews. Drug discovery. 2025. doi:10.1038/s41573-025-01236-y

Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.

Słabicki M. Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Molecular cell. 2025;85(16):3184-3201.e14. doi:10.1016/j.molcel.2025.07.019

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

Apfelbaum AA, Morin E, Sturm D, et al. A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. Nature communications. 2025;16(1):7018. doi:10.1038/s41467-025-61820-z

Integrative genomic identification of therapeutic targets for pancreatic cancer.

Guo JA, Gong D, Evans K, et al. Integrative genomic identification of therapeutic targets for pancreatic cancer. Cell reports. 2025;44(9):116191. doi:10.1016/j.celrep.2025.116191

Genomic landscape and immunological profile of glioblastoma in East Asian patients.

Zhong S, Wu B, Dubois F, et al. Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine. 2025;6(8):102217. doi:10.1016/j.xcrm.2025.102217

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.

Lightbody ED, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nature cancer. 2025. doi:10.1038/s43018-025-01006-0